Updated:
Forge Therapeutics
Forge Therapeutics (now Blacksmith Medicines) develops metalloenzyme-targeted medicines. No public data on leadership, funding, or operations available.
Forge Therapeutics
Forge Therapeutics, now operating as Blacksmith Medicines, has not publicly disclosed a founding year, named principals, or leadership team on its website. The firm's website describes a purpose-built platform for human metalloenzyme-targeted medicines, but no details on wealth origin, capital structure, or investment strategy are available. The company's geographic footprint is unclear; listed offices span Pasadena, Palo Alto, Hamburg, Boston, San Diego, Houston, Cambridge, Mississauga, and Indianapolis, but the current operational hub is unknown. No confirmed portfolio companies, deals, or co-investors are cited in public sources. No recent operational events from the past 24 months are verifiable. Team size, asset-class mix, and deployment figures remain undisclosed. The lack of public information on governance, succession, or structural differentiators limits further analysis. The firm's rebranding to Blacksmith Medicines may signal a strategic shift, but no substantive data supports a detailed profile.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
—
Country
United States
City
Pasadena, Palo Alto, Hamburg, Boston, San Diego, Houston, Cambridge, Mississauga, Indianapolis
Corporate office
—
Sector focus
Frequently asked questions
Who runs investment decisions at Forge Therapeutics?
Forge Therapeutics has not publicly disclosed its leadership team or investment decision-makers. The firm's website does not list any executives or principals as of the latest available information.
How does Forge Therapeutics source proprietary deal flow?
No information about deal flow sourcing is publicly available. The firm's website does not describe its investment process or deal origination methods.
Is Forge Therapeutics structured as a single family office or does it operate more like a venture firm?
Forge Therapeutics' structure is not publicly disclosed. The firm's website states it operates a platform for metalloenzyme-targeted medicines, but does not specify whether it is a family office or an investment vehicle.
Does Forge Therapeutics participate in fund commitments or only direct deals?
No public information exists on whether Forge Therapeutics makes fund commitments or direct investments. The firm's investment approach is not described in available sources.
What investment stages does Forge Therapeutics typically target?
Forge Therapeutics has not publicly stated its target investment stages. The firm's focus appears to be on therapeutic development, but no stage-specific details are available.
Which sectors does Forge Therapeutics explicitly avoid?
Forge Therapeutics has not published any excluded sectors. The firm's website centers on metalloenzyme-targeted human medicines, but avoidance criteria are not disclosed.
How is Forge Therapeutics related to Blacksmith Medicines?
Forge Therapeutics rebranded as Blacksmith Medicines, according to the firm's website. The relationship appears to be a name change, but no official announcement or explanation is publicly available.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: